Scleroderma Therapeutics Market Size, Sector / Industry Report & Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Scleroderma Therapeutics Market


The global Scleroderma Therapeutics market size is projected to reach US$ 2.55 billion by 2026, from US$ 1.8 billion in 2020, at a CAGR of 6% during 2021-2026. The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis. Lack of curative therapies and high prevalence of off-label drug use are underlying factors spurring interest in rare disease markets.

This is expected to fuel the development of targeted biologics and small molecule combination therapies. Increasing prevalence of scleroderma and rising incidences of genetic mutations coupled with drastic changes in the environment are also expected to be the key factors driving the market. In addition, increasing disposable income levels, enabling a higher spending capacity, and presence of well-defined regulatory framework supporting emergence of effective therapies in developed regions fuel the market growth.

The emergence of first-in-class curatives that are currently undergoing clinical development will also boost market growth over the forecast period. Furthermore, supplemental approvals for existing treatment options will reinforce growth.

Comorbidities associated with this disease account for the involvement of a wide range of drug classes prescribed in first- and second-line treatment of the condition. Among the indications, Pulmonary Arterial Hypertension (PAH) garnered the maximum sales. Medication for this comorbidity includes more than one drug class and several branded drugs. In addition, the two approved drugs in this market, bosentan, and iloprost are used to target PAH.

Market Segmentation, Outlook & Viewpoint: Global Scleroderma Therapeutics Market

Drug Class Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
Immunosuppressors
  
Phosphodiesterase 5 Inhibitors - PHA
  
Endothelin Receptor Antagonists
  
Prostacyclin Analogues
  
Calcium Channel Blockers
  
Analgesics
  
Others

Indication Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
Systemic
  
Localized

Key Players, Recent Developments & Regional Insights: Global Scleroderma Therapeutics Market

On the basis of drug class, the market is segmented into immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, analgesics, and others. Without a curative therapy for this disease, an expansive range of drug classes are prescribed to provide symptomatic relief. Immunosuppressants hold prominence as this class contains several biologics from established players such as Roche. Biologics and small molecule immunosuppressants are a growing segment with several pipeline drugs for scleroderma focusing on this class.

Novel therapies including Lenabasum and Ofev are expected to enter within the forecast period that are classed under ˜other drug classes. PDE-5 inhibitors market by drug classes are facing headwinds due to patent expiration of Revatio that bring down the revenue. ERAs remain in focus as this class of drugs mostly includes branded therapies and due to their use in the treatment of the indication with high incidence i.e. PAH.

Indication Insights

Based on indication, the scleroderma therapeutics market is categorized into localized and systemic scleroderma. The indications falling under systemic scleroderma include SSc-induced symptoms and conditions that range from interstitial lung disease to pulmonary arterial hypertension. Systemic indications account for majority of share due to use of high-priced immunosuppressants.

Localized scleroderma currently holds a small share in this market but is expected to grow over the forecast period with the expected launch of a first-in-class therapy, FCX-013 by Fibrocell. Fibrocells FCX-013 holds orphan drug and fast track designation and if approved, it would be the first gene therapy for localized scleroderma. This treatment aims to arrest the fibrosis in the early stages of the disease. Lenabasum by Corbus Pharmaceuticals is the first oral therapy with high curative potential targeting diffuse cutaneous systemic sclerosis that is associated with a high burden of comorbidities.

Regional Insights

North America was the dominance regional market in 2018. Access to recently developed immunosuppressants coupled with favorable reimbursement scenario is the key revenue driver. Europe trails with a lower share as compared to U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma.

In developing regions, generics and OTC drugs are the mainstay therapy for scleroderma and its symptoms. The Japan market although experiencing price cuts has faster access to new orphan therapies. Expected increase in access to biosimilar and generic immunosuppressants will drive growth in Latin America and MEA regions.
Scleroderma Therapeutics Market Share Insights

Some of the key companies in the market are F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex.
The market is highly fragmented with Roche leading with a commanding market position. Roches Cellcept, Actemra, Rituxan, and Esbriet drew the highest revenue in 2018. The underlying factor is high preference for immunosuppressants in the treatment of scleroderma induced PAH and ILD. With growth in penetration of this class of drugs and their improved efficacy in comparison to existing alternatives - cyclophosphamide, methotrexate, and mycophenolate mofetil - these therapies will reign until the launch of curatives that are undergoing clinical development.

Key Insights Covered: Global Scleroderma Therapeutics Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Scleroderma Therapeutics industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Scleroderma Therapeutics industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Scleroderma Therapeutics industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Scleroderma Therapeutics industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Scleroderma Therapeutics industry.

Research Methodology: Global Scleroderma Therapeutics Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other